Abstract P1-05-20: Validation of the HER2 Activation Response Predictive Signature (HARPS) as a Predictive Biomarker for HER2+ Therapy Response in the Neoadjuvant Setting
Emanuel Petricoin(George Mason University), Shridar Ganesan(Rutgers, The State University of New Jersey), Mridula George(Rutgers, The State University of New Jersey), Julia Wulfkuhle(University of California, San Francisco), Deborah Toppmeyer(Rutgers, The State University of New Jersey), Rosa I. Gallagher(George Mason University), Niloofar Ramezani(Virginia Commonwealth University), Gregory Riedlinger(Rutgers, The State University of New Jersey), L. A. Liotta, Coral Omene(Rutgers, The State University of New Jersey)
Cited by 0
Related Papers
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983
BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function
|Cell|2001|681
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
|Cancer Cell|2022|335